Press Releases Cytokinetics, Incorporated Deutsche Boerse AG

Equities

KK3A

US23282W6057

Real-time Estimate Tradegate Other stock markets 12:07:55 2024-06-17 EDT			5-day change	1st Jan Change
49.2 ^EUR	-1.60%		+2.89%	-32.70%

01:30pm	Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants	CI
06-11	Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants	07:30am	AQ
Cytokinetics Incorporated : Regulation FD Presentation Form 8 K	06-05	PU
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06-04	AQ
Cytokinetics to Participate in June Investor Conferences	05-29	AQ
Cytokinetics Announces Closing of Public Offering of Common Stock	05-28	AQ
Cytokinetics Announces Pricing of Public Offering of Common Stock	05-22	AQ
Cytokinetics Announces Proposed Public Offering of Common Stock	05-22	AQ
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline	05-22	AQ
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology	05-17	AQ
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024	05-15	AQ
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress	05-13	AQ
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine	05-13	AQ
Cytokinetics: Q1 Earnings Snapshot	05-08	AQ
Cytokinetics Reports First Quarter 2024 Financial Results	05-08	AQ
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy	05-08	AQ
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586	05-08	AQ
Cytokinetics to Hold Annual Meeting of Stockholders	05-07	AQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05-02	AQ
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress	04-29	AQ
Cytokinetics to Announce First Quarter Results on May 8, 2024	04-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cytokinetics, Incorporated Deutsche Boerse AG

Equities

KK3A

US23282W6057

Press Releases

Filters